Parabolan 100 - Genetic Pharmaceuticals

Trenbolone hexahydrobenzylcarbonate was developed to meet clinical needs for a powerful anabolic with minimal dosing frequency. Under the name Parabolan, this compound was introduced in France by Negma Laboratoires, offering a biweekly injectable alternative to the veterinary-used trenbolone acetate. Its moderate androgenic nature and non-estrogenic action made it suitable for treating severe muscle loss and metabolic disorders. Though highly effective, Parabolan was withdrawn in 1997, ending its era in legitimate medicine.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Parabolan 100 by Genetic Pharmaceuticals, consult with your doctor or healthcare professional.